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ABSTRACT
Although microRNAs (miRNAs) play an important role in liver homeostasis, the 
extent to which they can be altered by Toxoplasma gondii infection is unknown. Here, 
we utilized small RNA sequencing and bioinformatic analyses to characterize miRNA 
expression profiles in the liver of domestic cats at 7 days after oral infection with 
T. gondii (Type II) strain. A total of 384 miRNAs were identified and 82 were differentially 
expressed, of which 33 were up-regulated and 49 down-regulated. Also, 5690 predicted 
host gene targets for the differentially expressed miRNAs were identified using the 
bioinformatic algorithm miRanda. Gene ontology analysis revealed that the predicted 
gene targets of the dysregulated miRNAs were significantly enriched in apoptosis. Kyoto 
Encyclopedia of Genes and Genomes analysis showed that the predicted gene targets 
were involved in several pathways, including acute myeloid leukemia, central carbon 
metabolism in cancer, choline metabolism in cancer, estrogen signaling pathway, fatty 
acid degradation, lysosome, nucleotide excision repair, progesterone-mediated oocyte 
maturation, and VEGF signaling pathway. The expression level of 6 upregulated miRNAs 
(mmu-miR-21a-5p, mmu-miR-20a-5p, mmu-miR-17-5p, mmu-miR-30e-3p, mmu-miR-
142a-3p, and mmu-miR-106b-3p) was confirmed by stem-loop quantitative reverse 
transcription PCR, which yielded results consistent with the sequencing data. These 
findings expand our understanding of the regulatory mechanisms of miRNAs underlying 
T. gondii pathogenesis and contribute new database information on cat miRNAs, opening 
a new perspective on the prevention and treatment of T. gondii infection.
INTRODUCTION
Toxoplasma gondii is a highly prevalent 
apicomplexan protozoan parasite, which can cause 
serious clinical illnesses in humans and animals [1]. It 
has been reported to chronically infect roughly one-third 
of the world’s human population [2]. T. gondii acquired 
during pregnancy may cause damage to the fetus and 
reactivation of latent infection can cause life-threatening 
encephalitis in immune-compromised individuals [3]. 
This parasite has an indirect two-host lifecycle, which 
is composed of asexual reproductive phase in the 
intermediate host and sexual reproductive phase in the 
definitive host (members of the Felidae family). The 
enteroepithelial sexual cycle of T. gondii is completed 
within 3 to 10 days after ingestion of intermediate host 
tissue containing T. gondii cysts. T. gondii can also 
spread throughout the cat’s body and affect many organs 
[4–7]. Hence, cats are unique in respect of their ability 
to accommodate both sexual and asexual reproductions 
of T. gondii, making cats a significant source of infection 
to humans and animals [2, 8].
Besides the adverse clinical consequences on 
humans and other intermediate hosts T. gondii can cause 
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disseminated and fatal infection in cats [4-7, 9]. Although 
any organ in the cat’s body can be affected, clinical cases 
related to hepatic and pulmonary damage are particularly 
important because they are associated with quicker 
mortality [6, 10–12]. Also, liver dysfunction, enlargement, 
icterus, cholangiohepatitis, vomiting, abdominal effusion, 
and ascites are complications that frequently occur in T. 
gondii-infected cats. Therefore, with the great need for the 
development of efficacious treatment interventions (due 
to the lack of a vaccine and limited efficacies of current 
therapeutics), it is important to identify the molecular 
mechanisms that underpin liver damage caused by T. 
gondii infection. However, information about the molecular 
pathways that regulate the interaction between T. gondii and 
hepatic tissues has been limited to a few studies [13, 14].
The feline genome already encodes roughly 3,182 
microRNA (miRNA) homologues, which can regulate the 
expression of signalling cascades that perform key cellular 
functions, such as cell cycle regulation, proliferation, 
differentiation, apoptosis, and carcinogenesis. miRNAs 
constitute a group of endogenous non-coding small 
RNAs (18 to 25 nucleotides [nt] long) that regulate 
gene expression by binding to mRNA and inhibiting 
translation [15–18]. miRNAs play an important role in 
liver homeostasis, and aberrant expression of miRNAs 
has been associated with a variety of liver diseases, such 
as viral hepatitis, hepatocellular carcinoma and fatty liver 
disease [19]. Alterations of host miRNA expression have 
also been observed in some parasitic infections, such as 
Cryptosporidium parvum, Plasmodium falciparum and T. 
gondii (reviewed in [20]), underscoring the potential role 
of miRNAs in mediating the interaction between T. gondii 
and host cells. Despite the impact of T. gondii infection on 
hepatic function the mechanisms underlying the alterations 
of hepatic miRNAs expression following acute T. gondii 
infection remain poorly understood.
In this study, we hypothesized that T. gondii 
infection alters the expression of hepatic miRNAs and that 
differentially expressed miRNAs mediate the interaction 
between T. gondii and cat’s liver. Here we use genome-
wide, small RNA sequencing to characterize the global 
miRNA transcriptional response of feline liver to infection 
with T. gondii (Type II) PRU strain. Our study provides 
a full picture of the hepatic miRNA repertoire during 
acute T. gondii infection in domestic cats, including novel 
miRNAs, involved in host cell cycle, apoptosis and anti-
T. gondii defense.
RESULTS
Confirmation of T. gondii infection in the 
cat livers
Under the conditions we used positive PCR results 
were obtained, providing laboratory confirmation of 
T. gondii infection in the livers of infected cats. RFLP 
analysis of the positive PCR amplicons of T. gondii B1 
gene revealed a restriction fragment pattern characteristic 
to T. gondii genotype II. The livers of control cats and 
negative PCR control yielded negative PCR results.
Analysis of miRNA expression
miRNA libraries of livers from two T. gondii-
infected or two control cat groups were successfully 
sequenced and sequencing data is summarized in Table 
1 and Table 2. Length distributions of clean reads in the 
libraries were between 20-24 nt (Figure 1A-1D). A very 
high intra-group correlation was detected between the 
two miRNA libraries of T. gondii-infected liver samples 
(R2 =0.989) (Figure 2A) and the two miRNA libraries 
of uninfected liver samples (R2 =0.99) (Figure 2B). The 
known and novel mature miRNAs in T. gondii-infected 
and control groups were summarized in Table 3 and Table 
4. Finally, through comparing T. gondii-infected and 
uninfected sRNA libraries, 82 differentially expressed 
miRNAs were identified, including 33 up-regulated and 
49 down-regulated miRNAs (Table 5).
Pathway analysis of miRNA targets
A total of 5690 predicted host targets were identified 
(Supplementary Table 2). Based on the predicted targets 
of the differentially expressed miRNAs GO enrichment 
analysis was performed in order to identify the biological 
processes, molecular functions and cellular components. 
The enriched GO terms of the biological processes, 
molecular functions and cellular components are shown 
in Figure 3, respectively. KEGG enrichment analysis 
showed that target genes were related to multiple 
pathways, including nucleotide excision repair, lysosome, 
vascular endothelial growth factor (VEGF) signaling, 
estrogen signaling, acute myeloid leukemia, central carbon 
metabolism in cancer, choline metabolism in cancer, 
fatty acid degradation, progesterone-mediated oocyte 
maturation, and renal cell carcinoma. The top 20 KEGG 
enrichment pathways are shown in Figure 4.
miRNA expression validation by qRT-PCR
Six miRNAs, including mmu-miR-21a-5p, mmu-
miR-20a-5p, mmu-miR-17-5p, mmu-miR-30e-3p, mmu-
miR-142a-3p, and mmu-miR-106b-3p, were selected for 
confirmation by real time PCR to verify the expression 
levels of the differentially expressed miRNAs using 
miRNA specific primers (Supplementary Table 1). The 
results confirmed that these selected miRNAs were 
differentially expressed between infected livers and 
uninfected livers and were consistent with the results 
obtained by RNA-sequencing analysis (Supplementary 
Figure 1). Data set from the RNA-sequencing experiment 
has been deposited in the GEO database under accession 
number PRJNA356106.
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DISCUSSION
Previous studies showed that T. gondii infection 
can alter the expression of host miRNAs, indicating that 
miRNAs may be involved in the pathogenesis of T. gondii 
infection [21–24]. Our results have also shown that acute 
T. gondii infection alters the level of miRNAs in the liver 
of domestic cats. In the present study, we used small RNA 
sequencing to identify cellular miRNAs and signaling 
pathways involved in the response of cats to T. gondii 
infection. Specifically, we determined miRNAs that are 
differentially expressed by comparing sham-infected to 
T. gondii-infected cat livers at 7 days after infection. This 
analysis identified 82 differentially expressed microRNAs, 
of which 33 were increased and 49 decreased. By using 
qRT-PCR, the expression level of six up-regulated miRNAs 
(mmu-miR-21a-5p, mmu-miR-20a-5p, mmu-miR-17-5p, 
mmu-miR-30e-3p, mmu-miR-142a-3p, and mmu-miR-
106b-3p) were consistent with the results obtained by 
sequencing analysis. Knowledge of molecular changes 
in human liver during the acute phase of toxoplasmosis 
is lacking due to the mild and subtle nature of this 
infection especially in immune-component individuals 
[1, 2]. Hence, these findings may serve as the basis for 
understanding the molecular mechanisms associated with 
hepatic pathology during acute T. gondii infection.
Differentially expressed miRNAs were associated 
with signalling pathways involved mainly in cell cycling, 
apoptosis, oncogenesis, and host defense. Among the 
differentially expressed miRNAs, miR-21a-5p, miR-
17-5p, miR-223-3p, miR-27a-5p, miR-126, and miR-
486 were significantly upregulated in T. gondii-infected 
livers compared to controls. Of note, the level of miR-
21a-5p expression was elevated in various cancer tissues, 
including rectal, gastric and lung tissues [25–27] and 
has been suggested to play a role in tumor biology [27]. 
The similarity between the expression of miR-21a-5p 
during T. gondii infection and various forms of cancers 
is interesting. One striking finding was the correlative 
link between upregulation of miR-17-92 in T. gondii-
infected human foreskin fibroblasts [28] and in human 
astrocyticglioma tissue [29]. The presence of RNA 
silencing machinery and small silencing RNAs in T. gondii 
genome [30] indicates that this parasite has the ability to 
use its own miRNAs to interrupt host cell functions in 
analogy to oncogenic viruses [31].
miR-17-5p, a key regulator of the G1/S phase 
cell cycle transition, was up-regulated in our study in 
agreement with others who reported overexpression 
of miR-17-5p in human and mouse spleen in response 
to T. gondii infection [21, 31]. T. gondii can increase 
miR-17~92 and miR-106b~25 that play key roles in the 
Table 1: Summary of small RNA sequencing data obtained in the present study
Library type Reads Bases Error rate Q20 Q30 GC content
Infected liver Group 1 10665548 0.533G 0.01% 96.21% 92.13% 49.65%
Infected liver Group 2 12569494 0.628G 0.01% 96.16% 92.13% 49.98%
Uninfected liver Group 1 11727706 0.586G 0.01% 96.24% 92.33% 49.56%
Uninfected liver Group 2 10273236 0.514G 0.01% 96.44% 92.60% 49.72%
Table 2: Summary of the standard bioinformatic quality check and cleaning of small RNAs
Library
Infected groups Uninfected groups
Infected liver
Group 1
Infected liver
Group 2
Uninfected liver
Group 1
Uninfected liver
Group 2
Total reads 10665548 (100.00%) 12569494 (100.00%) 11727706 (100.00%) 10273236 (100.00%)
N%>10% 531 (0.00%) 636 (0.01%) 606 (0.01%) 540 (0.01%)
Low quality 40551 (0.38%) 47641 (0.38%) 42076 (0.36%) 32984 (0.32%)
5_adapter_contamine 1247 (0.01%) 1565 (0.01%) 1026 (0.01%) 915 (0.01%)
3_adapter_null or 
insert_null
174157 (1.63%) 176650 (1.41%) 223708 (1.91%) 195007 (1.90%)
With ployA/T/G/C 10772 (0.10%) 12621 (0.10%) 7991 (0.07%) 6939 (0.07%)
Clean reads 10438290 (97.87%) 12330381 (98.10%) 11452299 (97.65%) 10036851 (97.70%)
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regulation of mammalian cell cycle by influencing the 
functionally intertwined pathways of apoptosis and G1/S 
cell cycle progression [32]. miR-17-5p targets mouse 
Bcl2l11, Zmat3, Aifm1, and Capn2 to increase host 
apoptotic process and targets mouse Ppp3r1 and Akt3 to 
promote cellular apoptosis process [21]. Also, miR-17-5p 
may function as both a tumor suppressor [33] and as an 
oncogenic activator [34] by targeting both anti- and pro-
proliferative genes and by competing with each other in 
different cellular contexts [35]. The effect of T. gondii 
infection on the expression of miRNAs (miR-30c-1, miR-
125b-2, miR-23b-27b-24-1, and miR-17~92 cluster genes) 
that have anti-apoptotic activity has been reported [36]. 
Modulating these apoptosis-related miRNAs with mimics 
or inhibitors can validate their roles in the dysregulation 
of host cell apoptotic machinery during T. gondii infection.
The miR-223-3p has been implicated in the 
regulation of inflammatory response [37] and granulocyte 
production and function [38], and can function as a tumor 
suppresser in osteosarcoma by regulating the osteosarcoma 
Figure 1: Length distribution of the small RNA expressions in the liver of domestic cats infected with Toxoplasma 
gondii compared to control cats. (A and B) Group 1 and group 2 of T. gondii-infected domestic cats; (C and D) Group 1 and group 2 of 
uninfected, control, domestic cats. Abbreviations: IL1, IL2, UL1, and UL2: infected liver 1, infected liver 2, uninfected liver 1, uninfected 
liver 2, respectively.
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cell cycle progression and proliferation [39]. The level 
of miR-223-3p was significantly increased in infected 
samples, suggesting that T. gondii infection of feline liver 
stimulates the production of miR-223-3p, which plays a 
role in the activation of inflammatory response elicited 
in response to T. gondii infection. This is concordant 
with a previous study showing that miRNAs, such as 
miR-146a and miR-155, known to activate immune and 
inflammatory responses can influence host response to T. 
gondii infection [40–43]. Also, the upregulation of miR-
27a-5p (a regulator of lipid metabolism-related genes) 
and miR-21-5p in the infected liver samples suggests 
that both miR-27a-5p and miR-21-5p play a role in host 
response to infection. This assumption is supported by the 
association between inhibition of miR-21 and increased 
Cryptosporidium parvum burden [29].
miR-126 is associated with tumorigenesis and has 
recently been found to modulate the survival and function 
of Plasmacytoid dendritic cells (pDCs) via positive 
regulation of the vascular endothelial growth factor 
(VEGF) signaling pathway [44]. miR-126 upregulation 
may activate Toll-like receptor (TLR)/MyD88 signalling 
in pDCs to secrete large amounts of type I interferons 
(IFNs), which is essential for host resistance to T. 
gondii infection. Also, the biological significance of T. 
gondii-induced upregulation of miR-486 may lie in its 
ability to augment the host defense mechanisms. miR-
486 has been shown to activate nuclear factor (NF)-κB 
signaling pathway [45], which leads to the production of 
proinflammatory cytokines, thereby providing a protection 
against T. gondii infection. Of note, both miR-486 and 
the NF-κB signaling pathway have oncogenic roles in 
human cancers, such as glioma progression [45].
The let-7 family is a key regulator of the innate 
immune response. The level of let-7i during protozoal 
infection with C. parvum infection was found reduced 
together with increase of TLR4 in biliary epithelial cells, 
contributing to cholangiocyte’s defense responses [46]. 
In line with this study our results revealed significant 
downregulation of mmu-let-7f-5p, mmu-let-7i-5p, mmu-
let-7a-5p, mmu-let-7g-5p, mmu-let-7e-5p, and mmu-let-
7c-5p in T. gondii-infected cat’s livers compared with 
controls. Finally, the fact that miRNAs are host-, tissue-, 
and strain-specific [47] explains why the expression of 
some miRNA (e.g. miR-712-3p, miR-511-5p and miR-
217-5p) that are dysregulated during T. gondii infection 
[48] was not altered in our study.
In conclusion, these findings provided new insight 
regarding the ability of T. gondii to alter the expression 
of 82 microRNAs in cat liver. Our study revealed that 
through reprogramming of hepatic miRNAs expression 
T. gondii influences the cellular microenvironment and 
host anti-T. gondii response, which are likely to play 
roles in the parasite pathogenesis. GO analysis revealed 
that the predicted targets of the differentially expressed 
miRNAs were involved in the regulation of cell cycle 
and most of the identified KEGG pathways were related 
to cancer. Considering the immunoregulatory effects of 
miRNAs and their ability to modulate crucial host cellular 
targets needed for T. gondii replication, miRNAs may 
Figure 2: Correlation analysis of the small RNA expressions in the livers of T. gondii-infected and uninfected cats. (A) 
Correlation analysis of small RNA expression levels between T. gondii-infected cats of group 1 and group 2 (IL1 vs IL2); (B) Correlation 
analysis of small RNA expression levels between uninfected cats of group 1 and group 2 (Ul1 vs UL2).
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Table 3: Known miRNA mapping
Criteria
Infected groups Uninfected groups
Infected liver 
Group 1
Infected liver
Group 2
Uninfected liver
Group 1
Uninfected liver
Group 2
Mapped mature 358 360 348 356
Mapped hairpin 273 274 266 268
Mapped uniq sRNA 2531 2604 2411 2409
Mapped total sRNA 3086174 3665542 3484600 3037510
Table 4: Novel miRNA mapping
Types
Infected liver
Group 1
Infected liver 
Group 2
Uninfected liver
Group 1
Uninfected liver
Group 2
Novel mature 69 76 75 73
Novel star 10 14 12 10
Novel hairpin 72 78 80 77
Mapped uniq sRNA 186 187 161 161
Mapped total sRNA 12381 12103 13702 7981
Table 5: Differentially expressed miRNAs
Type miRNA Fold change P-value P-adjustment
Up-regulated mmu-miR-21a-5p 2.564 1.32E-17 3.15E-15
 mmu-miR-20a-5p 1.610 3.26E-09 3.88E-07
 mmu-miR-339-5p 1.839 5.42E-06 0.0002
 mmu-miR-101a-3p 1.855 8.22E-06 0.0002
 mmu-miR-320-3p 1.507 9.27E-06 0.0002
 mmu-miR-195a-5p 1.805 1.33E-05 0.0003
 mmu-miR-126a-3p 1.486 2.05E-05 0.0003
 mmu-miR-23a-3p 1.585 2.13E-05 0.0003
 mmu-miR-140-3p 1.701 2.45E-05 0.0003
 mmu-miR-28a-5p 1.500 0.0002 0.0018
 mmu-miR-223-3p 1.917 0.0002 0.0023
 mmu-miR-30f 1.504 0.0002 0.0023
 mmu-miR-126a-5p 1.437 0.0003 0.0025
 mmu-miR-126b-3p 1.435 0.0003 0.0025
 mmu-miR-17-5p 1.436 0.0005 0.0036
(Continued )
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Type miRNA Fold change P-value P-adjustment
 mmu-miR-19b-3p 1.485 0.0007 0.0048
 mmu-miR-27a-5p 1.741 0.0011 0.0076
 mmu-miR-486b-3p 1.593 0.0011 0.0076
 mmu-miR-151-3p 1.338 0.0017 0.0093
 mmu-miR-27a-3p 1.389 0.0017 0.0093
 mmu-miR-486a-3p 1.571 0.0017 0.0093
 mmu-miR-99b-5p 1.359 0.0021 0.0106
 novel_1 1.998 0.0030 0.0134
 mmu-miR-3074-5p 1.315 0.0049 0.0202
 mmu-miR-30e-3p 1.325 0.0052 0.0211
 mmu-miR-24-3p 1.306 0.0055 0.0212
 mmu-miR-101c 1.052 0.0069 0.0252
 mmu-miR-378c 1.528 0.0069 0.0252
 mmu-miR-486a-5p 1.494 0.0075 0.0271
 mmu-miR-361-3p 1.379 0.0101 0.0342
 mmu-miR-106b-3p 1.255 0.0153 0.0451
 mmu-miR-142a-3p 1.690 0.0152 0.0451
 mmu-miR-142b 1.690 0.0152 0.0451
Down-regulated mmu-let-7f-5p -1.546 1.73E-07 1.38E-05
 mmu-let-7i-5p -1.705 1.37E-06 6.52E-05
 mmu-miR-365-3p -1.532 1.24E-06 6.52E-05
 mmu-miR-148a-3p -1.662 6.17E-06 0.0002
 mmu-miR-381-3p -2.264 4.87E-06 0.0002
 mmu-miR-370-3p -2.876 8.54E-06 0.0002
 mmu-miR-3071-5p -2.007 1.62E-05 0.0003
 mmu-miR-136-3p -1.987 2.23E-05 0.0003
 mmu-miR-30c-2-3p -1.683 6.94E-05 0.0009
 mmu-miR-128-3p -1.487 7.45E-05 0.0009
 mmu-miR-30d-5p -1.358 0.0002 0.0018
 mmu-let-7a-5p -1.426 0.0002 0.0023
 mmu-miR-340-5p -1.570 0.0002 0.0023
 mmu-let-7g-5p -1.349 0.0003 0.0023
 mmu-miR-493-5p -2.565 0.0003 0.0023
(Continued )
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Type miRNA Fold change P-value P-adjustment
 mmu-miR-218-5p -1.618 0.0003 0.0025
 mmu-miR-127-3p -1.517 0.0003 0.0026
 mmu-let-7e-5p -1.380 0.0006 0.0042
 mmu-miR-98-5p -1.452 0.0012 0.0077
 mmu-miR-409-3p -1.919 0.0013 0.0083
 mmu-let-7c-5p -1.572 0.0015 0.0089
 mmu-miR-139-5p -1.418 0.0015 0.0089
 mmu-miR-129b-3p -1.526 0.0017 0.0093
 mmu-miR-129-5p -1.526 0.0018 0.0095
 mmu-miR-382-3p -2.192 0.0019 0.0096
 mmu-miR-193b-3p -1.554 0.0020 0.0102
 mmu-miR-429-3p -1.738 0.0021 0.0102
 mmu-miR-181b-5p -1.485 0.0023 0.0109
 mmu-miR-1b-5p -1.752 0.0024 0.0110
 mmu-miR-1a-3p -1.751 0.0024 0.0111
 mmu-miR-450a-5p -1.536 0.0025 0.0112
 mmu-miR-423-3p -1.296 0.0034 0.0148
 mmu-miR-328-3p -1.452 0.0035 0.0148
 mmu-miR-532-5p -1.316 0.0048 0.0200
 mmu-miR-148a-5p -1.521 0.0055 0.0212
 mmu-miR-499-5p -1.473 0.0055 0.0212
 novel_115 -2.137 0.0059 0.0223
 mmu-miR-425-5p -1.490 0.0080 0.0283
 mmu-miR-299a-3p -1.481 0.0091 0.0319
 mmu-miR-200a-3p -1.500 0.0099 0.0342
 mmu-miR-30b-5p -1.305 0.0104 0.0350
 mmu-miR-30e-5p -1.486 0.0108 0.0356
 mmu-miR-200a-5p -1.410 0.0110 0.0358
 mmu-miR-26a-5p -1.260 0.0113 0.0363
 mmu-miR-99a-5p -1.379 0.0125 0.0396
 mmu-miR-409-5p -1.705 0.0127 0.0398
 mmu-miR-92a-3p -1.350 0.0132 0.0409
 mmu-miR-129-1-3p -1.769 0.0146 0.0446
 mmu-miR-148b-3p -1.277 0.0167 0.0484
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Figure 4: The top 20 enriched pathways of the predicted host targets of the differentially expressed miRNAs.
Figure 3: GO enrichment analysis of predicted gene targets of differentially expressed miRNAs. Abbreviations: IL vs UL: 
infected liver vs uninfected liver, BP: biological process, MF: molecular function, CC: cellular component.
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hold promise as biomarkers for prediction of disease 
progression. Finally, miRNA pathways that are stimulated 
during infection may offer potential targets for therapeutic 
control of toxoplasmosis.
MATERIALS AND METHODS
Ethics statement
This study was performed in strict accordance 
with the recommendations set forth in the Animal Ethics 
Procedures and Guidelines of the People’s Republic 
of China. All animal experiments were reviewed and 
approved by the Animal Ethics Committee of Lanzhou 
Veterinary Research Institute, Chinese Academy of 
Agricultural Sciences (Approval No. LVRIAEC2014-009). 
Liver tissue collection was performed as a terminal 
procedure under isoflurane anesthesia and all efforts were 
made to minimize suffering.
Animals, parasite infection and sample collection
Twelve, 3 month-old, domestic cats (Felis catus) of 
the Chinese Li Hua breed were purchased from a local 
breeder and were housed in a controlled environment. 
The cats belonged to two litters, six cats per litter. These 
12 cats were randomly allocated to four groups (two 
infected and two control) with three cats per group. 
Before the experiment, all cats were confirmed to be 
free from T. gondii using the modified agglutination test 
and free of major viral infections (e.g. feline calicivirus 
and coronavirus, feline immunodeficiency virus, 
feline leukemia virus, and feline parvovirus) based 
on serological examination. Cats were maintained on 
commercial cat diets (Royal Canine Inc., St. Charles, MO, 
USA) and water ad libitum during the 3 weeks prior to 
experimentation in order to allow cats to acclimate and 
to minimize any potential dietary influence on the study 
results. During the experiment cats were individually fed 
once daily based on daily energy requirements and water 
was available ad libitum.
Toxoplasma gondii strain used in this study was 
the PRU strain (Genotype II), which is maintained in our 
laboratory by passage through Kunming mice as described 
previously [49]. T. gondii type II was used in this study 
because it seems to be the predominant genotype 
circulating in cats [50–52]. Also, the PRU strain is able to 
produce brain tissue cysts in mouse and oocysts in the gut 
of cats and is thus a suitable candidate for a standardized 
challenge model in cats. The number of T. gondii cysts was 
determined using an optical microscope and was adjusted 
to 100 cysts mL−1 in phosphate buffered saline (PBS), pH 
7.4. Each cat was infected by intragrastric inoculation with 
100 cysts in 1 mL PBS. Control cats were sham-infected 
with PBS only. Livers were harvested 7 days post infection 
(7 dpi) in order to allow sufficient time for the infection to 
be established in the liver [1]. Collected livers were rinsed 
extensively in saline, flash frozen in liquid nitrogen, and 
stored at −80°C until processing.
Detection of infection in the liver
Genomic DNA was extracted from the collected 
liver samples using TIANamp Genomic DNA kit 
according to the manufacturer’s recommendations 
(TianGen™, Beijing, China). Then, a semi-nested PCR 
targeting T. gondii B1 gene was performed to detect T. 
gondii infection [53]. DNA samples giving positive B1 
amplification were genotyped using PCR-restriction 
fragment length polymorphism analysis as described 
previously [54].
RNA extraction and qualification
Total RNA was prepared individually from the 
cryo-preserved liver tissues of the cats using TRIzol 
Reagent according to the manufacturer's instructions 
(Invitrogen Co. Ltd). RNA degradation and contamination 
was checked on 1% agarose gels. RNA purity was 
evaluated using the NanoPhotometer® spectrophotometer 
(IMPLEN, CA, USA). RNA concentration was determined 
using Qubit® RNA Assay Kit in Qubit® 2.0 Flurometer 
(Life Technologies, CA, USA). RNA integrity was 
assessed using the RNA Nano 6000 Assay Kit of the 
Agilent Bioanalyzer 2100 system (Agilent Technologies, 
CA, USA).
RNA sequencing library preparation and 
transcriptomic analysis
RNA samples from T. gondii-infected and non-
infected livers collected at 7 dpi were sent to Beijing 
Novogene Bioinformatics Institute for Illumina 
sequencing. To analyze miRNAs by sequencing, a total 
of 3 μg RNAs of three pooled samples from each group 
were used for the construction of four small RNA (sRNA) 
libraries, which were subjected to sequencing on a Hi-seq 
2500 platform. Raw data (raw reads) of fastq format were 
firstly processed through custom perl and python scripts. 
In this step, clean reads were obtained by removing reads 
containing ploy-N, with 5’ adapter contaminants, without 
3’ adapter or the insert tag, containing ploy A or T, or G or 
C and low quality reads from raw data. At the same time, 
Q20, Q30 and GC-content of the raw data were calculated. 
Then, we chose a certain range of length from clean reads 
to do all downstream analyses. Next, the small RNA tags 
were mapped to the feline reference genome sequence 
using Bowtie software [55]. The following parameters 
were used: -k [valid alignments per read], 1; -m [number 
of possible alignments], 10; -l [seed length], 25; --best 
[optimal alignments]).
Mapped small RNA tags were used to look for 
known miRNA. miRBase20.0 was used as reference, 
and modified software mirdeep2 [56] and srna-tools-cli 
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were used to obtain the potential miRNA and draw the 
secondary structures. Custom scripts were used to obtain 
the miRNA counts and base bias on the first position of 
identified miRNA with certain length and on each position 
of all identified miRNA, respectively. To remove tags 
originating from protein-coding genes, repeat sequences, 
rRNA, tRNA, snRNA, and snoRNA, small RNA tags were 
mapped to RepeatMasker, Rfam database or those types of 
data from the specified species itself.
The available software miREvo [57] and mirdeep2 
[56] were integrated to predict novel miRNA through 
exploring the secondary structure, the dicer cleavage 
site and the minimum free energy of the small RNA tags 
unannotated in the former steps. miRNA expression levels 
were estimated with TPM (transcript per million) units 
[58]. Differential expression analysis of infected versus 
control groups was performed using the DESeq R package 
(1.8.3). The P-values was adjusted using the Benjamini & 
Hochberg method. Corrected P-value of 0.05 was set as 
the threshold for significantly differential expression by 
default.
Predicting the target gene of miRNA was performed 
by psRobot_tar in miRanda [59]. Gene Ontology (GO) 
enrichment analysis was used to categorize the target 
genes of the differentially expressed miRNAs. GOseq 
based Wallenius non-central hyper-geometric distribution 
[60], which can adjust for gene length bias, was 
implemented for GO enrichment analysis. The enrichment 
of target genes in KEGG pathways were tested by the 
software KOBAS [61].
Validation of miRNA expression
The stem-loop quantitative reverse transcription 
PCR was used to validate the results of miRNA expression 
analysis as described previously [21, 62]. Stem-loop RT-
PCR was performed on ABI PRISM® 7500 Sequence 
Detection System using SYBR Green qPCRSuperMix 
according to the manufacturer's protocol (Invitrogen). All 
qRT-PCR reactions were performed in three replicates. 
Gene expressions were calculated by 2−ΔΔCT relative 
expression method as previously described [63]. snRNA 
U6 was used as normalization control in qRT-PCR.
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